Benzinga | Jun 28, 2021 07:06AM EDT

Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On ZN-c3 And ZN-c5 And Two Potentially Registrational Trials For ZN-c3, With The First Trial Already Initiated

Reports additional ZN-c3 Phase 1 interim monotherapy data, demonstrating increased tumor reduction and durability in the exceptional responder population, as well as newly confirmed responses and an additional unconfirmed PR in USC

Potential accelerated approval path identified for monotherapy use of ZN-c3 in USC following End-of-Phase 1 FDA meeting, with registrational study recently initiated

Company will seek FDA guidance on a potentially registrational trial for a tumor-agnostic, novel predictive biomarker-enabled ZN-c3 trial, which is expected to initiate by year-end

Orphan drug and rare pediatric disease designations granted for ZN-c3 in combination with chemotherapy for osteosarcoma, trial expected to initiate in 3Q 2021

Interim data from ZN-c5 Phase 1 clinical trial supports its potential best-in-class safety and tolerability profiles in monotherapy and in combinations

Company to host webcast event today, June 28, 2021 at 8:30 a.m. EDT